The United States has now ordered a total of 500 million Moderna vaccine doses to date, with 110 million set for delivery in the fourth quarter and 90 million to be delivered in the first quarter of 2022.
Moderna, which has supplied 217 million doses of its shot to the US government as of Monday.
In its new guidance, the CDC says, “fully vaccinated people no longer need to wear a mask outdoors, except in certain crowded settings and venues.”
“We got to make that transition,” Fauci said. “If you are going into a completely crowded situation where people are essentially falling all over each other, then you wear a mask.”
The company and the Biomedical Advanced Research and Development Authority (BARDA) had initially signed a $483 million deal for the vaccine in July last year, which was later increased to about $1 billion.
As of March 31, 2021, the remaining available funding net of revenue earned under the BARDA Contract, prior to the increased payment, was $317 million, Moderna said in a regulatory filing.
Data firm IHS Markit said on Friday its flash US manufacturing PMI increased to 60.6 in the first half of this month. That was the highest reading since the series started in May 2007 and followed a final reading of 59.1 in March.
Economists polled by Reuters had forecast the index rising to 60.5 in early April. A reading above 50 indicates growth in manufacturing, which accounts for 11.9% of the US economy.
The U.S. Centers for Disease Control and Prevention (CDC) is investigating the death of an Oregon woman and the hospitalisation of another in Texas after receiving Johnson & Johnson's (JNJ.N) COVID-19 vaccine, state health officials said.
The incidents come as advisers to the CDC are set to meet on Friday to consider whether it is safe to resume injections of the single-dose vaccine, while senior health officials prepare for a green light.
The US Centers for Disease Control and Prevention (CDC) advisory panel will meet on April 23, according to a notice posted on the regulator's website.
US health regulators recommended earlier this week that use of the J&J vaccine be paused after reports of six cases of rare brain blood clots in women.
The move comes a week after European regulators said they had found a possible link between AstraZeneca's COVID-19 vaccine and a rare blood clotting problem that had led to a small number of deaths.
Johnson & Johnson's (J&J) single dose vaccine - most COVID-19 shots are delivered over two doses - and AstraZeneca's low-cost vaccine are seen as vital tools in the fight against a pandemic that has claimed more than three million lives.
8 The E-IPO system will electronically connect investors, share registrars with brokers / TRE Certificate holders, banks via 1LINK, and the shares custodial company, Central Depository Company (CDC) on a real-time basis with a simplified end-to-end customer experience.